This discrepancy is thought to arise from interspecies differences; however, a definite mechanism for the antihypertensive/cardioprotective effect of GLP1RAs in humans is lacking.41,42 Previously, liraglutide, a long-acting GLP1RA, was shown to reduce BP via indirect action of ANP34; however, reports in healthy volunteers43 and T2D patients44 found no evidence of GLP1–ANP axis in humans. The gene discussed is NPPA; the disease is type 2 diabetes mellitus.